Net Loss Per Share Attributable to Common Stockholders (Tables)

12 Months Ended

Dec. 31, 2024

Earnings Per Share [Abstract]

Schedule of Calculation for Basic and Diluted Net Loss Per Share

The following table presents the calculation for basic and diluted net loss per share (in thousands, except share and per share data):


		Year Ended December 31,
		2024				2023				2022
Numerator:
Net loss		$	(705,809	)		$	(214,118	)		$	(289,811	)
Accretion of convertible preferred stock to redemption value			—				(4,338	)			(301	)
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares			(39,347	)			(44,497	)			(40,975	)
Cumulative undeclared dividends on Series C preferred shares			(1,174	)			(3,011	)			(2,841	)
Net loss attributable to common stockholders		$	(746,330	)		$	(265,964	)		$	(333,928	)
Denominator:
Weighted-average common shares outstanding, basic and diluted			119,849				63,306				63,032
Net loss per share attributable to common stockholders, basic and diluted		$	(6.23	)		$	(4.20	)		$	(5.30	)

Schedule of Antidilutive Securities Excluded From the Computation of Earnings Per Share

The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share for each period, as the impact of including them would have been anti-dilutive. As disclosed in Note 9, the Company issued a warrant for $100 million in shares of the Company’s Class A common stock. As per the terms of the warrant, potentially dilutive shares are based on the latest equity financing price. The warrant was terminated for no consideration on December 31, 2024.


		As of December 31,
		2024				2023				2022
Stock options outstanding			—				210,000				210,000
Convertible preferred stock			—				63,525,953				62,692,927
AstraZeneca warrant			—				1,744,991				1,744,991
Mpirik holdback liability			—				8,724				—
SEngine holdback liability			—				41,436				—
Unvested RSUs			6,873,974				—				—
Allen & Company warrant			—				150,000				—
Total potentially dilutive shares			6,873,974				65,681,104				64,647,918